What is Leerink Partnrs’ Forecast for RCUS Q1 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities researchers at Leerink Partnrs issued their Q1 2026 EPS estimates for Arcus Biosciences in a research report issued on Wednesday, February 26th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($0.55) for the quarter. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. Leerink Partnrs also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.06) EPS, Q4 2026 earnings at ($0.11) EPS and FY2029 earnings at $0.79 EPS.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The firm had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million.

Other research analysts have also recently issued reports about the stock. Bank of America cut their price target on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating on the stock in a report on Wednesday, February 19th. Morgan Stanley dropped their target price on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the company from $18.00 to $24.00 in a research note on Wednesday. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Arcus Biosciences currently has a consensus rating of “Buy” and a consensus target price of $30.25.

Arcus Biosciences Stock Performance

RCUS stock opened at $10.89 on Thursday. Arcus Biosciences has a twelve month low of $9.85 and a twelve month high of $20.00. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -3.46 and a beta of 0.84. The business’s fifty day simple moving average is $13.37 and its two-hundred day simple moving average is $15.40. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Institutional Investors Weigh In On Arcus Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Arcus Biosciences by 2.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after purchasing an additional 833 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Arcus Biosciences by 2.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,781 shares of the company’s stock worth $471,000 after purchasing an additional 843 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Arcus Biosciences by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after buying an additional 1,117 shares during the last quarter. R Squared Ltd acquired a new position in Arcus Biosciences during the 4th quarter valued at about $26,000. Finally, Teacher Retirement System of Texas raised its stake in Arcus Biosciences by 19.2% in the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after buying an additional 2,410 shares during the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Insider Activity at Arcus Biosciences

In other Arcus Biosciences news, CFO Robert C. Goeltz II sold 3,594 shares of the stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the sale, the chief financial officer now directly owns 60,138 shares of the company’s stock, valued at approximately $902,070. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was purchased at an average price of $10.18 per share, for a total transaction of $201,564.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. This represents a 0.78 % increase in their position. The disclosure for this purchase can be found here. 12.30% of the stock is currently owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.